TIDMGENI
RNS Number : 1605Z
GENinCode PLC
21 January 2022
21 January 2022
GENinCode Plc
("GENinCode" or the "Company")
Proposed independent directorate appointment
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease,
announces its intention to appoint Professor Huon Gray CBE, to the
Board as an independent non-executive director.
Huon has 30 years' experience practising as a consultant
cardiologist for the NHS and private sector, with particular
experience in cardiovascular risk assessment and interventional
cardiology. Huon served as the National Clinical Director for Heart
Disease in the Department of Health and then NHS England from
2012-2019, advising government, all party parliamentary groups, the
NHS and NICE on healthcare delivery and reform. He is a former
President of the British Cardiac Society (now the British
Cardiovascular Society) and was previously Chair of the
International Committee of the American College of Cardiology.
In 2018, Huon was awarded the honour of Master of the American
College of Cardiology, the only recipient outside of the US, and
the Mackenzie Medal by the British Cardiovascular Society in 2014
in recognition of his services to British cardiology. In 2019, he
was made a CBE for his services to cardiology.
Huon's exposure to the US healthcare system through his work
with the American College of Cardiology over 15 years, in roles
such as Trustee and Chair of its Governance Committee, will support
the Company as it targets the US as one of its primary markets.
Additionally, during Huon's tenure at NHS England, he acted as a
liaison with industry and Academic Health Science Networks, helping
deliver healthcare in the NHS through encouraging the adoption of
innovation and new technology.
Huon will be appointed to the board of GENinCode following
finalisation of the terms of his appointment and the completion of
the necessary regulatory due diligence in accordance with the AIM
Rules.
In addition, GENinCode anticipates appointing an additional
independent non-executive director in the short-term. A suitably
qualified US-based candidate has been identified that is an
experienced healthcare industry and US FDA regulatory veteran and
whom the Board believes will be very additive to GENinCode's
future.
Further announcements will be made at the appropriate time.
Bill Rhodes, Chair of GENinCode Plc, commented: "We are
delighted to have Huon join the Board, subject to completion of the
necessary formalities. Huon has extensive and expansive experience
in clinical cardiology and through his relationships globally, and
particularly in the US and the UK, coupled with his deep
appreciation for the benefits both patients and practitioners will
gain from the use of our products, there is no question he will add
tremendous value to the Board, the Company and our
shareholders."
Matthew Walls, CEO of GENinCode Plc, added: "Huon's background
and vast experience as a leading cardiologist in both the UK and
the US will be invaluable to the Company as we look towards
commercialisation later in 2022. Importantly, he shares our
excitement about the potential of the Company's portfolio of
products to drastically improve the current standard of care
worldwide."
Professor Huon Gray CBE commented: "I am delighted to be asked
to join the Board of GENinCode at this important stage.
Cardiovascular risk assessment in the US and UK currently comprises
a series of questions related to conventional risk factors, with no
genetic risk assessment. This is despite family history being one
of the most significant contributing risk factors to an
individual's likelihood of suffering from cardiovascular disease.
Consequently, the Company's portfolio of diagnostic products have
significant potential to improve the standard of care for millions
who every year suffer from cardiovascular disease."
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode@walbrookpr.com
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United
States through GENinCode U.S. Inc and in Europe through GENinCode
S.L.U.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict disease onset.
About Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death
globally, taking an estimated 17.9 million lives each year. CVD is
a group of disorders of the heart and blood vessels and include
coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths
are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and
stroke are unhealthy diet, physical inactivity, tobacco use and
harmful use of alcohol. The effects of behavioural risk factors may
show up in individuals as raised blood pressure, raised blood
glucose, raised blood lipids, and overweight and obesity. These
"intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke,
heart failure and other complications.
Cessation of tobacco use, reduction of salt in the diet, eating
more fruit and vegetables, regular physical activity and avoiding
harmful use of alcohol have been shown to reduce the risk of
cardiovascular disease. Health policies that create conducive
environments for making healthy choices affordable and available
are essential for motivating people to adopt and sustain healthy
behaviours.
Identifying those at highest risk of CVDs and ensuring they
receive appropriate treatment can prevent premature deaths. Access
to noncommunicable disease medicines and basic health technologies
in all primary health care facilities is essential to ensure that
those in need receive treatment and counselling.
CVD causes a quarter of all deaths in the UK and is the largest
cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years.
CVD is largely preventable, through lifestyle changes and a
combination of public health and NHS action on smoking and tobacco
addiction, obesity, tackling alcohol misuse and food
reformulation.
Genetic risk assessment can help early detection and treatment
of CVD to help patients live longer, healthier lives. Many people
are still living with undetected, high-risk conditions such as high
blood pressure, raised cholesterol, and atrial fibrillation (AF).
Progress continues in the NHS to identify and diagnose people
routinely knowing their 'ABC' (testing and monitoring of AF, Blood
pressure and Cholesterol) set out in the NHS 10 Year plan.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADZGZMRGZGZZM
(END) Dow Jones Newswires
January 21, 2022 02:00 ET (07:00 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genincode (LSE:GENI)
Historical Stock Chart
From Apr 2023 to Apr 2024
